Detection of microRNA using a polydopamine mediated bimetallic SERS substrate and are-circulated enzymatic amplification system

Detection of microRNA using a polydopamine mediated bimetallic SERS substrate and are-circulated enzymatic amplification system
复制标题

使用聚多巴胺介导的双金属 SERS 底物和循环酶扩增系统检测 microRNA

DOI:
10.1007/s00604-018-3174-y
复制
发表时间:
2019-02-01
期刊:
影响因子:
5.7
通讯作者:
Yu, Meng
Yu, Meng
中科院分区:
化学2区
文献类型:
--
作者:
Jiang, Ningjing;Hu, Yongjun;Yu, Meng

文献摘要

被引文献

相似文献

描述了一种用于测定与各种形式的癌症相关的微小RNA的表面增强拉曼散射(Sers)方法。该基底由功能化的金-银纳米结构组成,并通过使用再循环酶放大系统(REAS)来强烈增强灵敏度。聚多巴胺既作为还原剂又作为底物的保护剂。它被用来连接金芯和银卫星。由Au@PDA@Ag纳米复合材料组成的独特热点改善了拉曼信号和灵敏度。PDA的还原特性可以防止金属银的易氧化,从而保持高的拉曼活性。为了提高测定的灵敏度,开发了再循环酶促扩增系统,其中切口核酸内切酶触发核酸反应系统进入扩增循环。通过将纳米基底和磁性分离集成到REAS中,可以通过Sers(最佳在1586 cm(-1)的拉曼带)检测microRNA,检测限低至0.2 fM。在我们看来,该检测为研究肿瘤基因的表达提供了一条令人兴奋的新途径。因此,它在癌症诊断中具有广阔的前景。
A surface-enhanced Raman scattering (SERS) method is described for the determination of microRNA that is associated with various forms of cancer. The substrate consists of functionalized gold-silver bimetallic structure, and the sensitivity is strongly enhanced by making use of a re-circulated enzymatic amplification system (REAS). Poly-dopamine acts as both a reductant and a protective of the substrates. It was employed to link the gold core and silver satellite. The unique hot spots consisting of a Au@PDA@Ag nanocomposite improve the Raman signal and sensitivity. The reductive feature of PDA can prevent the susceptible oxidation of metallic silver to maintain the high Raman activity. To improve the sensitivity of the assays, a re-circulated enzymatic amplification system was developed in which the nicking endonuclease triggers the nucleic acid reaction system to enter an amplified cycle. By integrating the bimetallic nanosubstrate and magnetic separation into the REAS, microRNA can be detected by SERS (best at the Raman band of 1586cm(-1)) with a limit of detection as low as 0.2 fM. In our perception, the assay provides an exciting new avenue to study the expression of tumor genes. Thus, it holds vast promise in cancer diagnosis.